デフォルト表紙
市場調査レポート
商品コード
1439970

免疫調節剤の世界市場:洞察、競合情勢、市場予測:2030年

Immunomodulators - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
免疫調節剤の世界市場:洞察、競合情勢、市場予測:2030年
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の免疫調節剤の市場規模は、2024年から2030年までの予測期間中に5.19%のCAGRで拡大すると予測されています。免疫調節剤の需要は、主に喘息、アレルギー性疾患、がん、多発性硬化症など、様々な慢性疾患の世界の増加によって後押しされています。加えて、多発性硬化症の治療におけるポネシモド、オザニモド、ラキニモドなどの免疫治療薬の開発に関する臨床試験の急増、ドラッグデリバリー技術の進歩、クローン病の治療における早期の免疫調節剤治療の採用増加、関節リウマチなどの免疫疾患の治療に関するアンメットニーズの高さ、薬剤の上市と承認の増加などが、2024年~2030年の予測期間中、免疫調節剤市場全体の成長に寄与しています。

免疫調節剤市場は、様々な要因によって製品需要が伸びていますが、その主要な要因の1つは、世界中で慢性疾患が増加していることです。米国がん協会(American Cancer Society)が行った最新の調査によると、2040年までに、人口の増加と高齢化により、世界のがん罹患者数は2,750万人、がん死亡者数は1,630万人に達すると推定されています。経済的に移行しつつある国々では、喫煙、不健康な食事、運動不足、出産の減少など、リスクを増大させる要因がますます蔓延しているため、将来の負担はおそらくさらに大きくなると思われます。免疫調節薬は、主に多発性骨髄腫や他のいくつかのがんを治療する経路を標的とする薬剤群です。これらの薬剤には、あるタンパク質を減少させ、他のタンパク質を増加させることによって免疫系に直接働きかけるなど、様々な作用の仕方があります。したがって、がんの罹患率の増加は、今後数年間、免疫調節剤の需要を増加させるとみられています。

当レポートでは、世界の免疫調節剤市場について調査し、市場の概要とともに、タイプ別、適応症別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 免疫調節剤市場レポートのイントロダクション

第2章 免疫調節剤市場のエグゼクティブサマリー

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 免疫調節剤市場の主な要因分析

  • 免疫調節剤市場の促進要因
  • 免疫調節剤市場の抑制要因と課題
  • 免疫調節剤市場の機会

第5章 免疫調節剤市場におけるポーターのファイブフォース分析

第6章 免疫調節剤市場の概要

  • タイプ別
  • 適応症別
  • 地域別

第7章 免疫調節剤市場の企業と製品プロファイル

  • Pfizer Inc.
  • Petrovax
  • Acrotech Biopharma, Inc.
  • Astellas Pharma Inc.
  • Horizon Therapeutics plc
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Biocon
  • Bristol-Myers Squibb Company
  • Teva Pharmaceuticals
  • Zydus Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Johnson & Johnson Services, Inc
  • Lilly

第8章 KOL の見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightについて

第11章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: Immunomodulators Market in Global (2021-2030)
  • Table 4: Immunomodulators Market in Global by Type (2021-2030)
  • Table 5: Immunomodulators Market in Global by Indication (2021-2030)
  • Table 6: Immunomodulators Market in Global by Geography (2021-2030)
  • Table 7: Immunomodulators Market in North America (2021-2030)
  • Table 8: Immunomodulators Market in North America by Country (2021-2030)
  • Table 9: Immunomodulators Market in the US (2021-2030)
  • Table 10: Immunomodulators Market in Canada (2021-2030)
  • Table 11: Immunomodulators Market in Mexico (2021-2030)
  • Table 12: Immunomodulators Market in Europe (2021-2030)
  • Table 13: Immunomodulators Market in Europe by Country (2021-2030)
  • Table 14: Immunomodulators Market in France (2021-2030)
  • Table 15: Immunomodulators Market in Germany (2021-2030)
  • Table 16: Immunomodulators Market in the United Kingdom (2021-2030)
  • Table 17: Immunomodulators Market in Italy (2021-2030)
  • Table 18: Immunomodulators Market in Spain (2021-2030)
  • Table 19: Immunomodulators Market in the Rest of Europe (2021-2030)
  • Table 20: Immunomodulators Market in Asia-Pacific (2021-2030)
  • Table 21: Immunomodulators Market in Asia-Pacific by Country (2021-2030)
  • Table 22: Immunomodulators Market in China (2021-2030)
  • Table 23: Immunomodulators Market in Japan (2021-2030)
  • Table 24: Immunomodulators Market in India (2021-2030)
  • Table 25: Immunomodulators Market in Australia (2021-2030)
  • Table 26: Immunomodulators Market in South Korea (2021-2030)
  • Table 27: Immunomodulators Market in Rest of Asia-Pacific (2021-2030)
  • Table 28: Immunomodulators Market in the Rest of the World (2021-2030)
  • Table 29: Immunomodulators Market in RoW by Region (2021-2030)
  • Table 30: Immunomodulators Market in the Middle East (2021-2030)
  • Table 31: Immunomodulators Market in Africa (2021-2030)
  • Table 32: Immunomodulators Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: Immunomodulators Market in Global (2021-2030)
  • Figure 4: Immunomodulators Market in Global by Type (2021-2030)
  • Figure 5: Immunomodulators Market in Global by Indication (2021-2030)
  • Figure 6: Immunomodulators Market in Global by Geography (2021-2030)
  • Figure 7: Immunomodulators Market in North America (2021-2030)
  • Figure 8: Immunomodulators Market in North America by Country (2021-2030)
  • Figure 9: Immunomodulators Market in the US (2021-2030)
  • Figure 10: Immunomodulators Market in Canada (2021-2030)
  • Figure 11: Immunomodulators Market in Mexico (2021-2030)
  • Figure 12: Immunomodulators Market in Europe (2021-2030)
  • Figure 13: Immunomodulators Market in Europe by Country (2021-2030)
  • Figure 14: Immunomodulators Market in France (2021-2030)
  • Figure 15: Immunomodulators Market in Germany (2021-2030)
  • Figure 16: Immunomodulators Market in the United Kingdom (2021-2030)
  • Figure 17: Immunomodulators Market in Italy (2021-2030)
  • Figure 18: Immunomodulators Market in Spain (2021-2030)
  • Figure 19: Immunomodulators Market in the Rest of Europe (2021-2030)
  • Figure 20: Immunomodulators Market in Asia-Pacific (2021-2030)
  • Figure 21: Immunomodulators Market in Asia-Pacific by Country (2021-2030)
  • Figure 22: Immunomodulators Market in China (2021-2030)
  • Figure 23: Immunomodulators Market in Japan (2021-2030)
  • Figure 24: Immunomodulators Market in India (2021-2030)
  • Figure 25: Immunomodulators Market in Australia (2021-2030)
  • Figure 26: Immunomodulators Market in South Korea (2021-2030)
  • Figure 27: Immunomodulators Market in Rest of Asia-Pacific (2021-2030)
  • Figure 28: Immunomodulators Market in the Rest of the World (2021-2030)
  • Figure 29: Immunomodulators Market in RoW by Region (2021-2030)
  • Figure 30: Immunomodulators Market in the Middle East (2021-2030)
  • Figure 31: Immunomodulators Market in Africa (2021-2030)
  • Figure 32: Immunomodulators Market in South America (2021-2030)
  • Figure 33: Market Drivers
  • Figure 34: Market Barriers
  • Figure 35: Marker Opportunities
  • Figure 36: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0651

Immunomodulators Market By Type (Immunosuppressants And Immunostimulants), Indication (Cancer, Respiratory, HIV, And Others), and geography is expected to grow at a steady cagr forecast till 2030 owing to the rising prevalence of chronic diseases and the increase in adoption of early immunomodulator therapy

The global immunomodulators market is estimated to grow at a CAGR of 5.19% during the forecast period from 2024 to 2030. The demand for immunomodulators is primarily being boosted by the increasing figures of various chronic diseases such as asthma, allergic conditions, cancer, multiple sclerosis, and others, worldwide. In addition, a surging number of ongoing clinical trials for the development of immunotherapeutic agents, such as ponesimod, ozanimod, and laquinimod, in the treatment of multiple sclerosis, advancements in drug delivery technologies, rising adoption of an early immunomodulator therapy for the treatment of Crohn's disease, the presence of the high unmet clinical needs about treatment for immune disorders, such as rheumatoid arthritis, the increasing drugs launches and approval among others are thereby contributing to the overall growth of the immunomodulators market during the forecast period from 2024-2030.

Immunomodulators Market Dynamics:

The immunomodulators market is witnessing a growth in product demand owing to various factors, one of the key factors being the increasing number of chronic diseases across the globe. As per the latest study done by the American Cancer Society, it is estimated that by 2040, the global burden of cancer is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths simply due to the growth and aging of the population. The future burden will probably be even larger due to the increasing prevalence of factors that increases risk, such as smoking, unhealthy diet, physical inactivity, and fewer childbirths, in economically transitioning countries. Immunomodulators are a group of drugs that mainly target the pathways that treat multiple myeloma and a few other cancers. They have many ways to work, including working on the immune system directly by turning down some proteins and turning up others. Thus, the increasing incidence of cancer will increase the demand for immunomodulators in the upcoming years.

Further, according to MSIF 2020 report, 2.8 million people were living with multiple sclerosis (MS) in 2020, around the globe. Immunomodulators or receptor modulators are indicated for the treatment of patients with relapsing forms of MS. They help to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. Thus, the increasing prevalence of MS will increase the demand for immunomodulators in the market.

The element driving the rise of this vertical is also the existence of high unmet clinical needs concerning the treatment of immunological illnesses, such as rheumatoid arthritis. Because of their decreased risk of side effects when compared to other available medications, these immunotherapies are anticipated to become more popular in the upcoming years. Due to the limited options, which are limited to TNF inhibitors, there is an increasing demand for alternative treatments for rheumatoid arthritis, which is anticipated to create attractive growth possibilities for this industry.

Further, rising strategic activities will also create a positive impact on the growth of the market. For instance, in March 2022, Themis Medicare Ltd., a pharmaceutical company headquartered in Mumbai, announced the approval of its antiviral drug VIRALEX® by the Drug Controller General of India (DCGI). VIRALEX® is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defense response to viral infections. Therefore, the above-mentioned factors are contributing to the growth of the immunomodulators market during the forecast period from 2024-2030.

However, side effects related to drugs, stringent regulatory framework, and others may restrict the immunomodulators market growth.

Immunomodulators Market Segment Analysis:

Immunomodulators market by Type (Immunosuppressants and Immunostimulants), Indication (Cancer, Respiratory, HIV, and Others), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World)

In the drug type segment of the immunomodulators market, the immunosuppressants category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the advantages and applications associated with the segment.

Immunosuppressive drugs, often known as immunosuppressive agents, are medications that inhibit or block immune system activation. It can reduce the high reactivity of the immune system which is causing auto-immune diseases and other chronic disorders.

These drugs prevent the rejection of transplanted organs and tissues, and treat autoimmune diseases or diseases that are most likely of autoimmune origin such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, sarcoidosis, focal segmental glomerulosclerosis, Crohn's disease, Behcet's Disease, pemphigus, and ulcerative colitis, and treat some other non-autoimmune inflammatory diseases such as long term allergic asthma control.

The increasing number of cases of cancers will also increase the demand for immunosuppressant drugs. For instance, as per GLOBOCAN 2021, in 2020, nearly 1,324,413 new cases of cancer were reported in India. Rapalogs, a family of immunosuppressive drugs including rapamycin (sirolimus), everolimus, temsirolimus, and deforolimus are indicated for the treatment of various malignancies. Thus, the increasing figures for cancers will increase the demand for immunosuppressants in the market.

Further, the increasing product launches, approvals, and other strategic activities on immunosuppressant drugs will drive the market of the segment. For instance, in November 2020, Lupin launched generic immunosuppressant Tacrolimus capsules in the American market after its alliance partner Concord Biotech received approval for the product from the US health regulator. The company has launched Tacrolimus capsules USP in the strengths of 0.5 mg, 1 mg, and 5 mg after Concord Biotech received approval for its abbreviated new drug application (ANDA) from the United States Food and Drug Administration (US FDA),

Therefore, the advantages and applications offered by immunosuppressants are predicted to contribute to the increasing demand for this segment thereby driving the growth of the overall immunomodulators market during the forecast period.

North America is expected to dominate the Overall Immunomodulators Market:

Among all the regions, North America is estimated to account for the largest share of the Immunomodulators market in the year 2023. Owing to factors such as the upsurge in the aging population susceptible to autoimmune disorders, a surging population base suffering from chronic diseases such as asthma, allergic conditions, cancer, multiple sclerosis, and others, and the presence of key players in the region, is expected to aid in the growth of the North America Immunomodulators market. Furthermore, high disposable income, sophisticated healthcare infrastructure, and regulatory approval for new drugs, also helped the market growth in this region.

According to a report published by the National Multiple Sclerosis Society (2023), in 2020, more than 1 million people suffering from multiple sclerosis resided in the United States. Immunomodulatory drugs for multiple sclerosis (MS) control autoimmune damage to the central nervous system (CNS) by reducing immune cell numbers, altering their function, or blocking their access to the brain and spinal cord. Thus, the increasing figures of such autoimmune diseases in the region will increase the demand for immunomodulatory drugs, thereby propelling the market of immunomodulatory in North America.

Coupled with the factors mentioned above, strategic activities such as product launches and approvals, mergers, acquisitions, partnerships, and others also help in boosting regional product demand. For instance, in November 2022, Provention Bio, Inc., received Biologics License Application (BLA) approval from FDA for TZIELD (teplizumab-mzwv), an anti-CD3-directed antibody, for intravenous use, as the first and only immunomodulatory treatment to delay the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older with stage 2 T1D.

Also, in August 2019, AbbVie announced that the US FDA approved RINVOQ(TM) (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). RINVOQ is a targeted immunomodulator (TIM) therapy. Thus, such strategic steps help to increase the demand for Immunomodulators, thereby driving the North America immunomodulators market forward during the forecast period.

Immunomodulators Market Key Players:

Some of the key market players operating in the Immunomodulators market include Pfizer Inc., Petrovax, Acrotech Biopharma, Inc., Astellas Pharma Inc., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Biocon, Bristol-Myers Squibb Company, Teva Pharmaceuticals, Zydus Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Johnson & Johnson Services, Inc., Lilly., and others.

Recent Developmental Activities in the Immunomodulators Market:

In April 2023, The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) granted ADvantage Therapeutics' immunotherapy AD04 an Innovation Passport for the treatment of Alzheimer's disease. The designation, under the regulator's Innovative Licensing and Access Pathway (ILAP), will fast-track a potential route to market for AD04 by providing collaborative opportunities with UK institutes like the National Institute for Health and Care Excellence (Nice).

In October 2019, Pandion Therapeutics, Inc., and Astellas Pharma Inc., signed a license and collaboration agreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of the pancreas.

In January 2019, KYORIN Holdings, Inc., announced that its wholly-owned subsidiary KYORIN Pharmaceutical Co., Ltd. entered into a collaboration and license agreement with aTyr Pharma, Inc., for Japan about ATYR1923, aTyr's novel immunomodulator. The agreement grants Kyorin an exclusive license to develop and commercialize ATYR1923 for interstitial lung diseases in Japan.

Key Takeaways from the Immunomodulators Market Report Study

Market size analysis for current immunomodulators market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the immunomodulator market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global immunomodulators market.

Various opportunities available for the other competitor in the immunomodulators market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current immunomodulators market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for immunomodulators market growth in the coming future?

Target Audience who can be benefited from this Immunomodulators Market Report Study

Immunomodulators products providers

Research organizations and consulting companies

Immunomodulators-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in immunomodulators

Various End-users who want to know more about the immunomodulators market and the latest technological developments in the immunomodulators market.

Frequently Asked Questions for the Immunomodulators Market:

1. What are immunomodulators?

Immunomodulators are agents that can enable the body to fight cancer, infection, or other disorders by stimulating or suppressing the immune system.

2. What is the market for global immunomodulators?

The global immunomodulators market is estimated to grow at a CAGR of 5.19% during the forecast period from 2024 to 2030.

3. What are the drivers for the global Immunomodulators market?

The demand for immunomodulators is primarily being heightened by the increasing incidence of chronic diseases including asthma, cancer, allergic conditions, multiple sclerosis, and other chronic diseases. In addition, increasing adoption of early immunomodulator therapy for the treatment of Crohn's disease, the presence of high unmet clinical needs about treatment for immune disorders, the availability of generic immunomodulators, and increasing drug launches and approvals, among others, thereby contribute to the overall growth of the immunomodulators market during the forecast period from 2024-2030.

4. Who are the key players operating in the global immunomodulators market?

Some of the key market players operating in the immunomodulators market include Pfizer Inc., Petrovax, Acrotech Biopharma, Inc., Astellas Pharma Inc., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Biocon, Bristol-Myers Squibb Company, Teva Pharmaceuticals, Zydus Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Johnson & Johnson Services, Inc., Lilly., and others.

5. Which region has the highest share in the immunomodulators market?

North America is expected to dominate the overall immunomodulators market during the forecast period from 2024-2030. Factors such as the upsurge in the aging population susceptible to autoimmune disorders, the surging population base suffering from chronic diseases such as asthma, allergic conditions, cancer, multiple sclerosis, and others, and the presence of key players in the region, among others will positively impact the North American immunomodulators market. Furthermore, high disposable income, sophisticated healthcare infrastructure, regulatory approval for new drugs, and high awareness about immunotherapy also helped the market growth in this region.

Table of Contents

1.Immunomodulators Market Report Introduction

2. Immunomodulators Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Immunomodulators Market Key Factors Analysis

  • 4.1. Immunomodulators Market Drivers
    • 4.1.1. Increasing incidence of various chronic diseases such as asthma, allergic conditions, cancer, multiple sclerosis, and others
    • 4.1.2. The presence of high unmet clinical needs regarding treatment for immune disorders
    • 4.1.3. The increase in the adoption of early immunomodulator therapy
  • 4.2. Immunomodulators Market Restraints and Challenges
    • 4.2.1. Side effects related to drugs
    • 4.2.2. Stringent regulatory framework
  • 4.3. Immunomodulators Market Opportunities
    • 4.3.1. Presence of a robust number of drugs in the pipeline
    • 4.3.2. Rising incorporation of immunomodulatory nanosystems to improve therapeutic effects

5. Immunomodulators Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Immunomodulators Market Layout

  • 6.1. By Type
    • 6.1.1. Immunosuppressants
    • 6.1.2. Immunostimulants
  • 6.2. By Indication
    • 6.2.1. Cancer
    • 6.2.2. Respiratory
    • 6.2.3. HIV
    • 6.2.4. Others
  • 6.3. By Geography
    • 6.3.1. North America
      • 6.3.1.1. United States Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.1.2. Canada Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.1.3. Mexico Immunomodulators Market Size in USD million (2021-2030)
    • 6.3.2. Europe
      • 6.3.2.1. France Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.2.2. Germany Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.2.3. United Kingdom Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.2.4. Italy Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.2.5. Spain Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.2.6. Rest of Europe Immunomodulators Market Size in USD million (2021-2030)
    • 6.3.3. Asia-Pacific
      • 6.3.3.1. China Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.3.2. Japan Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.3.3. India Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.3.4. Australia Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.3.5. South Korea Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.3.6. Rest of the Asia-Pacific Immunomodulators Market Size in USD million (2021-2030)
    • 6.3.4. Rest of the World (RoW)
      • 6.3.4.1. Middle East Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.4.2. Africa Immunomodulators Market Size in USD million (2021-2030)
      • 6.3.4.3. South America Immunomodulators Market Size in USD million (2021-2030)

7. Immunomodulators Market Company and Product Profiles

  • 7.1. Pfizer Inc.
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Petrovax
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Acrotech Biopharma, Inc.
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. Astellas Pharma Inc.
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. Horizon Therapeutics plc
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Sun Pharmaceutical Industries Ltd.
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Merck & Co., Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Biocon
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Bristol-Myers Squibb Company
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Teva Pharmaceuticals
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Zydus Pharmaceuticals, Inc.
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. F. Hoffmann-La Roche Ltd
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. Amgen Inc.
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Johnson & Johnson Services, Inc
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Lilly.
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us